Our results uncover a novel Treg‐intrinsic role for ISG15 in dampening excessive type I IFN signalling, which may protect Tregs from the effects of an acute exposure to type I IFNs occurring in vivo during therapy for CHC or during disease reactivation in SLE. The gene discussed is ISG15; the disease is cryohydrocytosis.